Aga Clinical Trials — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$1,537,623	180
2024	Research	$55,080	103
2023	Research	$632	5
2022	Research	$1,581	2
2021	Research	$39,119	3
2020	Research	$166,107	2

Breakdown

Who paid Research payments · program years 2020–2025

AstraZeneca Pharmaceuticals LP $1,378,685 38 payments
Ipsen Innovation $210,737 236 payments
H. Lundbeck A S $166,107 2 payments
Eli Lilly and Company $40,348 4 payments
AbbVie, Inc. $2,133 4 payments
Moderna TX, Inc. $1,812 5 payments
Merck Sharp & Dohme Corporation $291 3 payments
Novo Nordisk AS $29 3 payments

Studies the money was for Research payments · program years 2020–2025

A Phase II Randomised Double blind Placebo controlled Study to Evaluate the Efficacy Safety and Tolerability of AZD6234 in Participants Living with Obesity or Overweight with Comorbidity $1,062,248 1 payment
Evaluate Efficacy & Safety of Eptinezumab Administered Intravenously in Subjects Experiencing Acute Attack of Migraine (RELIEF) $166,107 2 payments
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants $122,798 125 payments
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants $87,939 111 payments
A Phase II, Randomized, Double-blind, Single-dose, Placebo-controlled, 3-Period, 3-Treatment, Crossover, Multicenter Study to Compare the Bronchodilatory Effect and Safety of PT007 AS MDI to Placebo MDI and Open-Label Ventolin Evohaler in Adult Participants with Asthma MITCHELL $58,308 1 payment
A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS $53,811 8 payments
a phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd progression in participants with ckd and high blood pressure $46,201 8 payments
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease $40,293 3 payments
A Phase IIb Randomized Double blind Placebo controlled and Open label Active Comparator Study to Evaluate the Efficacy Safety and Tolerability of AZD5004 in Adults with Type 2 Diabetes Mellitus $21,964 1 payment
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Efficacy and Safety Study of Tezepelumab in Patients with Eosinophilic Esophagitis (CROSSING) $20,533 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.